Can one targeted drug still work after another fails? new trial aims to find out
NCT ID NCT06263543
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial is testing whether the drug sacituzumab govitecan (Trodelvy) can shrink tumors in people with a specific type of advanced breast cancer (HR+/HER2 low or ultra low) who have already received another targeted drug called T-DXd. The study will enroll 75 participants and measure how many respond to treatment. The goal is to see if using these drugs in sequence can help control the cancer longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sacituzumab govitecan (Trodelvy)
What this could lead to
If successful, this could show that sacituzumab govitecan remains effective even after prior treatment with T-DXd, offering a new treatment sequence option for people with this type of breast cancer.
What could go wrong
This is a small, early-phase (Phase 2) study with only 75 participants. It may not show enough benefit, or the drug could cause side effects like diarrhea or low blood cell counts. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Miami Cancer Institute at Baptist Health, Inc.
RECRUITINGMiami, Florida, 33176, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UCLA Jonsson Comprehensive Cancer Center
NOT_YET_RECRUITINGLos Angeles, California, 90404, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Winship Cancer Institute at Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••